ImmunityBio Inc
IBRX
Market Cap$2.53B
Close$
$-3.10
212.3% downside
Current Fair Value
212.3% downsideOvervalued by 212.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.53 Billion |
|---|---|
| Enterprise Value | $2.53 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-0.59 |
| Beta | -0.07 |
| Outstanding Shares | 853,162,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -5.99 |
|---|---|
| PEG | 179.85 |
| Price to Sales | - |
| Price to Book Ratio | -2.76 |
| Enterprise Value to Revenue | 81.32 |
| Enterprise Value to EBIT | -9.36 |
| Enterprise Value to Net Income | -7 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | -0.09 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About ImmunityBio Inc
171 employees
CEO: Patrick Soon-Shiong NantKwest (NASDAQ: NK) is an innovative, clinical-stage, immunotherapy company focused on harnessing the power of the innate immune system to treat cancer and infectious diseases. NantKwest is the leading producer of clinical dose forms ...